Citigroup Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $59

Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ: OLMA ) with a Buy and lowers the price target from $62 to $59.